Brainstorm Cell Therapeutics Inc. (BCLI)
| Market Cap | 11.70M +64.3% |
| Revenue (ttm) | n/a |
| Net Income | -10.52M |
| EPS | -0.95 |
| Shares Out | 11.03M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 56,501 |
| Open | 1.210 |
| Previous Close | 1.218 |
| Day's Range | 1.000 - 1.233 |
| 52-Week Range | 0.459 - 1.690 |
| Beta | 0.24 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 26, 2026 |
About BCLI
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company’s NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the deve... [Read more]
Financial Performance
Financial StatementsNews
Brainstorm Cell Therapeutics Earnings release: Q2 2026
Brainstorm Cell Therapeutics released its Q2 2026 earnings on August 27, 2026, summarizing the period's financial results.
Brainstorm Cell Therapeutics Quarterly report: Q2 2026
Brainstorm Cell Therapeutics has published its Q2 2026 quarterly earnings report on August 27, 2026.
BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
NEW YORK, Aug. 14, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial r...
BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman
Professor Jacob Frenkel Transitions to Senior Advisor Peter J. Pitts to lead NurOwn® into Phase 3b trial; advancing under the first Special Protocol Assessment ever granted for an ALS therapeutic cand...
BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine
Former FDA Associate Commissioner Peter Pitts and BrainStorm's Chaim Lebovits argue that regulation must keep pace with advances in biomarkers, AI, cell therapy and precision medicine NEW YORK, June 2...
Lunai Bioworks and BrainStorm launch foundation for neurological diseases
Lunai Bioworks’ (LNAI) wholly owned subsidiary BioSymetrics and BrainStorm (BCLI) announced a strategic collaboration and Letter of Intent to jointly discover, validate, and advance novel therapeutic ...
BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors
Former Senior FDA Official Joins Board as Company Prepares to Initiate Historic Phase 3b ALS Trial Under Special Protocol Assessment NEW YORK, May 28, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics...
Brainstorm Cell Therapeutics Registration statement: Registration filing
Brainstorm Cell Therapeutics filed a registration statement on May 21, 2026, providing details about a securities offering with the SEC.
BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market
$2.4 Million in H1 2026 Capital Raises Ahead of Phase 3b ENDURANCE Trial NEW YORK, May 19, 2026 /PRNewswire/ -- May 19, 2026 – BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of ...
BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
NEW YORK, May 15, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial re...
Brainstorm Cell Therapeutics Quarterly report: Q1 2026
Brainstorm Cell Therapeutics has published its Q1 2026 quarterly earnings report on May 15, 2026.
Brainstorm Cell Therapeutics Earnings release: Q1 2026
Brainstorm Cell Therapeutics released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update
Strategic $2.0 million post year-end financing and re-rating of BCLI shares underscore market confidence Company highlights durable long-term survival in Expanded Access Program (EAP) cohort supportin...
Brainstorm Cell Therapeutics Annual report: Q4 2025
Brainstorm Cell Therapeutics has published its Q4 2025 annual report on March 31, 2026.
Brainstorm Cell Therapeutics Earnings release: Q4 2025
Brainstorm Cell Therapeutics released its Q4 2025 earnings on March 31, 2026, summarizing the period's financial results.
Brainstorm Cell Therapeutics Secures Second $1 Million Strategic Placement; Total $2 Million Raised In February
NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced it has entered...
Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market
NEW YORK, Feb. 20, 2026 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced it has entered...
BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
NEW YORK , Nov. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial ...
Brainstorm Cell Therapeutics Quarterly report: Q3 2025
Brainstorm Cell Therapeutics has published its Q3 2025 quarterly earnings report on November 14, 2025.
Brainstorm Cell Therapeutics Earnings release: Q3 2025
Brainstorm Cell Therapeutics released its Q3 2025 earnings on November 14, 2025, summarizing the period's financial results.
Halper Sadeh LLC Encourages Brainstorm Cell Therapeutics Inc. Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Brainstorm Cell Therapeutics Inc. (OTCMKTS: BCLI) breached their fi...
Brainstorm Cell Therapeutics Earnings Call Transcript: Q2 2025
Management outlined focus on neurodegenerative disorder treatments, ongoing clinical programs, and capital sufficiency for 2025, while highlighting significant risks and uncertainties tied to forward-looking statements.
Brainstorm Cell Therapeutics Quarterly report: Q2 2025
Brainstorm Cell Therapeutics has published its Q2 2025 quarterly earnings report on August 14, 2025.
Brainstorm Cell Therapeutics Earnings release: Q2 2025
Brainstorm Cell Therapeutics released its Q2 2025 earnings on August 14, 2025, summarizing the period's financial results.
BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
Conference call and webcast scheduled for 8:30 a.m. Eastern Time Today, Thursday, August 14, 2025 NEW YORK , Aug. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading de...